We invest to extend and enhance human life
Our strategy is to create a diversified portfolio of 15-20 globally leading healthcare businesses companies with a goal, over a rolling 10-year basis, of delivering three to five companies in which we retain a significant ownership position to the point of product approval. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams.

Our business in numbers*

11

portfolio companies

£722m

value of life science portfolio

£578m

capital pool

14

members of the investment team

79%

investment team with PhDs

16

portfolio company board seats

Building the next generation of global leaders

We do this by founding, building and funding companies to turn exceptional science into transformational treatments to patients in areas of high unmet need.

Who we are

A strong sense of culture and social purpose

We invest to extend and enhance human life.

We have a strong, entrepreneurial culture, where everyone takes personal ownership for delivering Syncona’s mission. Our culture is underpinned by our values.

Purpose, culture and values

Driving value creation through strategy

We take a long-term approach to building leading life science companies, focusing on maximising value through the cycle. Our fundamental view is that value creation in life science comes by taking products into late development, product approval and, in some cases, beyond.

A team of experts

The life sciences investment team members have deep technical scientific backgrounds, supplemented by strong commercial experience ranging from venture capital investment to pharmaceutical launch. 

Our people

“Our strategy is clear. Syncona is building a sustainable, diversified portfolio of 15-20 companies over a rolling 10-year period.”

Melanie Gee
Chair, Syncona Ltd

Also in this section

Our differentiated model

We found, build and fund companies around exceptional science in areas of high unmet medical need, where there is potential to take product to market.

Find out more

Rapid translation of scientific research

Our platform enables the rapid translation of scientific research into companies with the potential to be global leaders.

Find out more

A data-driven investment process

Our data driven investment process leverages the team’s significant expertise.

Find out more

Founded to make a difference

Syncona was co-founded in 2012 by the Wellcome Trust, the premium charitable funder of life sciences in the UK. The business was set up to address the lack of long-term funding in UK life science by creating globally competitive, sustainable companies.

Find out more

*Unless stated all financials at 31 March 2021